NO994390L - Kombinasjonsterapi som anvender ileal gallesyretransportinhiberende benzotiepiner og HMG Co-A reduktaseinhibitorer - Google Patents
Kombinasjonsterapi som anvender ileal gallesyretransportinhiberende benzotiepiner og HMG Co-A reduktaseinhibitorerInfo
- Publication number
- NO994390L NO994390L NO994390A NO994390A NO994390L NO 994390 L NO994390 L NO 994390L NO 994390 A NO994390 A NO 994390A NO 994390 A NO994390 A NO 994390A NO 994390 L NO994390 L NO 994390L
- Authority
- NO
- Norway
- Prior art keywords
- benzothepines
- hmg
- combination therapy
- bile acid
- reductase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4066097P | 1997-03-11 | 1997-03-11 | |
PCT/US1998/003792 WO1998040375A2 (en) | 1997-03-11 | 1998-03-10 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
NO994390D0 NO994390D0 (no) | 1999-09-10 |
NO994390L true NO994390L (no) | 1999-11-04 |
Family
ID=21912237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO994390A NO994390L (no) | 1997-03-11 | 1999-09-10 | Kombinasjonsterapi som anvender ileal gallesyretransportinhiberende benzotiepiner og HMG Co-A reduktaseinhibitorer |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0971744A2 (no) |
JP (1) | JP2002500628A (no) |
CN (1) | CN1255864A (no) |
AU (1) | AU730024C (no) |
BG (1) | BG103793A (no) |
BR (1) | BR9808013A (no) |
CA (1) | CA2283575A1 (no) |
HU (1) | HUP0002395A3 (no) |
IL (1) | IL131872A0 (no) |
MX (1) | MXPA99008417A (no) |
NO (1) | NO994390L (no) |
NZ (1) | NZ337830A (no) |
PL (1) | PL336415A1 (no) |
RU (1) | RU2247579C2 (no) |
SK (1) | SK125099A3 (no) |
WO (1) | WO1998040375A2 (no) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6083497A (en) | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
AU2003241629B2 (en) * | 1999-04-19 | 2005-06-16 | Astrazeneca Ab | An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
AU2001247331A1 (en) * | 2000-03-10 | 2001-09-24 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
SE0003766D0 (sv) * | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
WO2002051396A1 (fr) * | 2000-12-26 | 2002-07-04 | Sankyo Company, Limited | Compositions pharmaceutiques contenant des derives de cyclobutene |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
PL216023B1 (pl) | 2001-09-08 | 2014-02-28 | Astrazeneca Ab | Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny |
HUP0500165A2 (en) | 2001-12-19 | 2006-09-28 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
WO2003053359A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
KR100990524B1 (ko) * | 2002-08-28 | 2010-10-29 | 아사히 가세이 파마 가부시키가이샤 | 신규한 4급 암모늄 화합물 |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
US7973030B2 (en) | 2004-02-27 | 2011-07-05 | Asahi Kasei Pharma Corporation | Benzothiazepine and benzothiepine compounds |
EP2995317A1 (en) | 2010-05-26 | 2016-03-16 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
CN103228270B (zh) | 2010-11-08 | 2016-02-10 | 阿尔比里奥公司 | 含ibat抑制剂和胆汁酸结合剂的药物组合 |
RU2591188C2 (ru) | 2010-11-08 | 2016-07-10 | Альбирео Аб | Ингибиторы ibat для лечения заболеваний печени |
CN107375291A (zh) | 2011-10-28 | 2017-11-24 | 鲁美纳医药公司 | 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂 |
MX354242B (es) | 2011-10-28 | 2018-02-20 | Lumena Pharmaceuticals Inc | Nhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas. |
MX2015013193A (es) | 2013-03-15 | 2016-04-15 | Lumena Pharmaceuticals Inc | Inhibidores del reciclaje de acidos biliares para el tratamiento de colangitis esclerosante primaria y enfermedad inflamatoria intestinal. |
JP2016514678A (ja) | 2013-03-15 | 2016-05-23 | ルメナ ファーマシューティカルズ エルエルシー | バレット食道と胃食道逆流性疾患を処置するための胆汁酸再利用阻害剤 |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
CN106794188B (zh) * | 2014-09-28 | 2022-12-02 | 华辉安健(北京)生物科技有限公司 | 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
EP3413877B1 (en) | 2016-02-09 | 2021-04-07 | Albireo AB | Oral cholestyramine formulation and use thereof |
ES2874546T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
WO2019032026A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
EP3802504B1 (en) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11802115B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
LT3921028T (lt) | 2019-02-06 | 2023-02-10 | Albireo Ab | Benzotiadiazepino junginiai ir jų naudojimas kaip tulžies rūgšties moduliatorių |
WO2020161216A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
JP2022519905A (ja) | 2019-02-12 | 2022-03-25 | ミルム ファーマシューティカルズ インコーポレイテッド | 胆汁酸塩排出ポンプ欠損症の患者における遺伝子型およびasbtiに対する用量依存的反応 |
JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
WO2021110885A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
TW202134223A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
AR120683A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
JP2023504647A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
IL293379A (en) | 2019-12-04 | 2022-07-01 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
CN112274648B (zh) * | 2020-11-23 | 2022-10-14 | 郑州大学 | 一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法 |
CN116583504A (zh) | 2020-12-04 | 2023-08-11 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
WO2024044183A1 (en) * | 2022-08-22 | 2024-02-29 | Enanta Pharmaceuticals, Inc. | Fused heterobicyclic antiviral agents |
-
1998
- 1998-03-10 CN CN98804995A patent/CN1255864A/zh active Pending
- 1998-03-10 AU AU64408/98A patent/AU730024C/en not_active Ceased
- 1998-03-10 EP EP98910075A patent/EP0971744A2/en not_active Withdrawn
- 1998-03-10 CA CA002283575A patent/CA2283575A1/en not_active Abandoned
- 1998-03-10 BR BR9808013-0A patent/BR9808013A/pt not_active IP Right Cessation
- 1998-03-10 PL PL98336415A patent/PL336415A1/xx unknown
- 1998-03-10 WO PCT/US1998/003792 patent/WO1998040375A2/en not_active Application Discontinuation
- 1998-03-10 SK SK1250-99A patent/SK125099A3/sk unknown
- 1998-03-10 RU RU99121514/15A patent/RU2247579C2/ru not_active IP Right Cessation
- 1998-03-10 IL IL13187298A patent/IL131872A0/xx unknown
- 1998-03-10 MX MXPA99008417A patent/MXPA99008417A/es unknown
- 1998-03-10 JP JP53959498A patent/JP2002500628A/ja not_active Abandoned
- 1998-03-10 HU HU0002395A patent/HUP0002395A3/hu unknown
- 1998-03-10 NZ NZ337830A patent/NZ337830A/en not_active Application Discontinuation
-
1999
- 1999-09-10 NO NO994390A patent/NO994390L/no not_active Application Discontinuation
- 1999-10-11 BG BG103793A patent/BG103793A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BR9808013A (pt) | 2001-09-25 |
NO994390D0 (no) | 1999-09-10 |
BG103793A (en) | 2000-07-31 |
WO1998040375A3 (en) | 1998-12-03 |
HUP0002395A3 (en) | 2002-12-28 |
WO1998040375A2 (en) | 1998-09-17 |
IL131872A0 (en) | 2001-03-19 |
SK125099A3 (en) | 2001-02-12 |
JP2002500628A (ja) | 2002-01-08 |
PL336415A1 (en) | 2000-06-19 |
CN1255864A (zh) | 2000-06-07 |
CA2283575A1 (en) | 1998-09-17 |
AU6440898A (en) | 1998-09-29 |
HUP0002395A2 (hu) | 2001-05-28 |
AU730024C (en) | 2004-08-05 |
AU730024B2 (en) | 2001-02-22 |
MXPA99008417A (es) | 2005-02-03 |
RU2247579C2 (ru) | 2005-03-10 |
EP0971744A2 (en) | 2000-01-19 |
NZ337830A (en) | 2001-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO994390D0 (no) | Kombinasjonsterapi som anvender ileal gallesyretransportinhiberende benzotiepiner og HMG Co-A reduktaseinhibitorer | |
DK1216247T3 (da) | Imidazoimidazoler og triazoler som anti-inflammatoriske midler | |
NO20010016L (no) | Benzotiepiner med aktivitet som inhibitorer for ileal gallesyretransport og opptak av taurokolat | |
ZA98376B (en) | Sulfamide-metalloprotease inhibitors | |
NO990296D0 (no) | HPPD-genet og inhibitorer | |
MXPA03003417A (es) | Formulacion oral que comprende un compuesto inhibidor del transporte biliar ileal y un inhibidor de reductasa hmgco-a. | |
DK0944590T3 (da) | Aminoguanidiner og alkoxyguanidiner som proteaseinhibitorer | |
GB2321641B (en) | Sulfamide-metalloprotease inhibitors | |
NO20001323L (no) | Dipeptid-apoptose-inhibitorer og deres anvendelse | |
NO993956L (no) | Fremgangsmåte for målfölging | |
IL135428A0 (en) | Ace inhibitor-mmp inhibitor combinations | |
DK0914124T3 (da) | Antithrombotisk, antiatherosclerotisk, farmaceutisk sammensætning omfattende et thienopyridinderivat og en HMG-CoA-reduktasehæmmer | |
AU9802798A (en) | Gas treating solution corrosion inhibitor | |
AU9197598A (en) | Inducing neurotransmitter and neuropeptide activity | |
AU8673598A (en) | Neuraminidase inhibitors | |
NO20000371D0 (no) | Aminoetylfenoksyeddiksyrederivater og legemidler for smertereduksjon og kalksteinfjerningsfremming i urin litiasis | |
DK1032559T3 (da) | Aminoalkylphenolderivater til behandling af depression og hukommelsessvigt | |
EP1232159A4 (en) | INHIBITORS OF BETA AMYLOID PEPTIDES | |
AU3721000A (en) | Corrosion inhibitor and process | |
AU8968598A (en) | Bovine footrot treatment and prevention | |
PT948483E (pt) | Inibidores da farnesil-transferase | |
HUP0201597A2 (en) | Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines | |
DK199901135A (da) | Fremgangsmåde og indretning til gennemførsel af økonomiske transaktioner | |
HU9700818D0 (en) | Pharmaceutical ointment against ekzema and psoriasis | |
GB9703335D0 (en) | Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |